Penile Squamous Cell Carcinoma Clinical Trial
Official title:
Molecular Characterization of Penile Cancers in Developing Countries
This study explores penile squamous cell carcinoma (PSCC) in Brazil, a rare cancer associated with factors like poor hygiene and HPV infection, using next-generation sequencing to investigate its genomic profiles in 24 deceased patients with advanced PSCC.
This study focuses on penile squamous cell carcinoma (PSCC), a rare cancer that is more prevalent in underdeveloped regions such as Africa, Asia, and South America, with Brazil having one of the highest incidence rates due to socioeconomic factors. PSCC is primarily associated with risk factors like poor local hygiene, smoking history, phimosis, and human papillomavirus (HPV) infection. The research aims to understand the genomic profiles of PSCC and their correlation with clinical characteristics, particularly in circumcised vs. non-circumcised populations in Brazil. The study will employ next-generation sequencing (NGS) on tumor specimens from 23 deceased patients with advanced PSCC who received treatment in Brazilian cancer sites. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02837042 -
Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT01807546 -
Oral Rigosertib for Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT03774901 -
Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT06353906 -
Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02496208 -
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02834013 -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
|
Phase 2 | |
Recruiting |
NCT03943602 -
Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen)
|
Phase 2 |